| Fitness Assessment in Young Adults Recovered From Lymphoma (NCT05188755) | University Hospital, Clermont-Ferrand | 2022-01-01 |
| A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin (NCT04998331) | Takeda | 2021-10-29 |
| Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT (NCT04629430) | University of Virginia | 2021-02-19 |
| Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers (NCT04072393) | Washington University School of Medicine | 2021-01-15 |
| A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. (NCT04671693) | Centre Leon Berard | 2020-12-24 |
| Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors (NCT03935282) | Wake Forest University Health Sciences | 2020-10-01 |
| Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma (NCT04459416) | Memorial Sloan Kettering Cancer Center | 2020-06-30 |
| Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation (NCT03755414) | Washington University School of Medicine | 2019-09-04 |
| A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation (NCT03942263) | Takeda | 2019-05-31 |
| A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant (NCT03739502) | University of Rochester | 2019-02-28 |
| Feasibility and Agreement of Remote Evaluation of Resting Heart Rate and Heart Rate Variability in Survivors of Hodgkin Lymphoma Treated With Chest Radiation (PILOT STUDY-SURVIVOR) (NCT03838627) | St. Jude Children's Research Hospital | 2019-02-05 |
| Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (NCT03598608) | Merck Sharp & Dohme LLC | 2018-10-17 |
| OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy (NCT03527628) | King Abdullah International Medical Research Center | 2018-01-01 |
| A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma (NCT02979522) | Takeda | 2017-09-06 |
| A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment (NCT02927769) | Bristol-Myers Squibb | 2017-03-28 |
| Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) (NCT02939014) | Takeda | 2016-11-07 |
| Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma (NCT02867618) | Columbia University | 2016-10-16 |
| Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (NCT02663297) | UNC Lineberger Comprehensive Cancer Center | 2016-06-07 |
| Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols (NCT02682667) | National Cancer Institute (NCI) | 2016-04-11 |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies (NCT02639559) | Washington University School of Medicine | 2016-03-31 |
| Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE (NCT02686346) | The Lymphoma Academic Research Organisation | 2016-03-01 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas (NCT02181218) | Washington University School of Medicine | 2015-02-04 |
| PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients (NCT02104427) | GPCR Therapeutics, Inc. | 2015-02-01 |
| Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (NCT02287311) | Baylor College of Medicine | 2015-02-01 |
| Molecular and Whole-body MR Imaging in Lymphomas (NCT02389101) | Turku University Hospital | 2014-10-01 |
| Occupational Status and Hematological Disease (NCT02057185) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2014-09-08 |
| Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality (NCT02378337) | Hospital Sao Rafael | 2014-09-01 |
| Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) (NCT02181738) | Bristol-Myers Squibb | 2014-08-12 |
| Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma (NCT01969435) | Washington University School of Medicine | 2014-03-19 |
| A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity (NCT02567851) | University of Birmingham | 2014-02-01 |
| Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma (NCT01956084) | Catherine Bollard | 2013-11-01 |
| Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma (NCT01874054) | Seagen Inc. | 2013-06-01 |
| Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A (NCT01858922) | Baylor College of Medicine | 2012-12-19 |
| Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (NCT01758042) | Massachusetts General Hospital | 2012-11-01 |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) (NCT01716806) | Seagen Inc. | 2012-10-31 |
| Tissue Collection for Studies of Lymph Cancer (NCT01676805) | National Cancer Institute (NCI) | 2012-09-21 |
| Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) (NCT01745354) | Robert Lowsky | 2012-08-01 |
| Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma (NCT01555853) | Washington University School of Medicine | 2012-07-01 |
| Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (NCT01333046) | Baylor College of Medicine | 2012-01-01 |
| Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma (NCT01468311) | National Cancer Institute (NCI) | 2011-10-11 |
| Preservation of Ovarian Function After Hematopoietic Cell Transplant (NCT01343368) | Masonic Cancer Center, University of Minnesota | 2011-07-01 |
| Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma (NCT01207921) | Washington University School of Medicine | 2011-04-28 |
| Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors (NCT01158118) | Washington University School of Medicine | 2011-04-01 |
| Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease (NCT00871702) | Washington University School of Medicine | 2010-10-01 |
| Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma (NCT01195766) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2010-07-01 |
| Personalised Program for Women Treated for Hodgkin Disease (NCT01188915) | Institut Paoli-Calmettes | 2010-07-01 |
| A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer (NCT01149668) | Pharmacyclics LLC. | 2010-06-01 |
| Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients (NCT01121120) | Tarix Pharmaceuticals | 2010-06-01 |
| Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients (NCT01018979) | GPCR Therapeutics, Inc. | 2010-02-01 |
| Brazilian Prospective Hodgkin Lymphoma Registry (NCT02589548) | Universidade Federal do Rio de Janeiro | 2009-10-01 |
| Pilot Study of Unrelated Cord Blood Transplantation (NCT00916045) | King's College Hospital NHS Trust | 2009-09-01 |
| Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma (NCT00901069) | Shams Shakil | 2009-05-01 |
| B-Receptor Signaling in Cardiomyopathy (NCT01135849) | Daniel Bernstein | 2008-11-01 |
| Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant (NCT00909948) | Massachusetts General Hospital | 2008-11-01 |
| Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma (NCT00733824) | Washington University School of Medicine | 2008-11-01 |
| A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) (NCT00779584) | Merck Sharp & Dohme LLC | 2008-10-17 |
| Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma (NCT00903890) | University of Rochester | 2008-08-01 |
| Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma (NCT00724984) | Pharmacyclics LLC. | 2008-07-01 |
| Functional Assessment of Cancer Therapy - Bone Marrow Transplant (NCT01490957) | King Faisal Specialist Hospital & Research Center | 2008-03-01 |
| A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma (NCT00636311) | Istituto Clinico Humanitas | 2008-02-01 |
| Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients (NCT00562224) | Pharmacyclics LLC. | 2007-11-01 |
| Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma (NCT00540007) | Washington University School of Medicine | 2007-09-06 |
| Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT (NCT00534989) | King Faisal Specialist Hospital & Research Center | 2007-09-01 |
| Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases (NCT00538551) | King Faisal Specialist Hospital & Research Center | 2007-01-01 |
| Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma (NCT00478959) | University Health Network, Toronto | 2006-12-01 |
| Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells (NCT00398411) | University of Cologne | 2006-10-01 |
| Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor (NCT00393380) | The Emmes Company, LLC | 2006-09-01 |
| Study of TPI 287 in Patients With Advanced Malignancies (NCT00113724) | Cortice Biosciences, Inc. | 2005-05-01 |
| Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma (NCT00148018) | University of Cologne | 2005-03-01 |
| Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease (NCT00534820) | King Faisal Specialist Hospital & Research Center | 2004-06-01 |
| Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy (NCT01078350) | Stanford University | 2004-05-01 |
| Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies (NCT00241358) | Washington University School of Medicine | 2004-05-01 |
| Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients (NCT01764230) | Masaryk University | 2004-01-01 |
| Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training (NCT00196885) | German Cancer Research Center | 2003-12-01 |
| LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma (NCT00062868) | Baylor College of Medicine | 2003-09-01 |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies (NCT00145613) | St. Jude Children's Research Hospital | 2003-06-01 |
| Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies (NCT00514722) | University of California, San Francisco | 2002-10-01 |
| Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer (NCT00039676) | National Cancer Institute (NCI) | 2002-07-08 |
| Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy (NCT00038558) | M.D. Anderson Cancer Center | 2001-11-01 |
| Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease (NCT00225173) | Stanford University | 2001-10-01 |
| Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease (NCT00388349) | Stanford University | 2001-09-01 |
| Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma (NCT00026208) | Stanford University | 2001-06-01 |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS (NCT00025662) | National Heart, Lung, and Blood Institute (NHLBI) | 2001-05-01 |
| A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy (NCT00261677) | Ortho Biotech Products, L.P. | 2000-08-01 |
| Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia (NCT00039910) | Pfizer | 2000-07-01 |
| Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET (NCT00188149) | University Hospital Carl Gustav Carus | 2000-05-01 |
| High Dose Chemotherapy Followed By PBSC Rescue for HD (NCT00186251) | Stanford University | 1998-03-01 |
| Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease (NCT00058773) | Baylor College of Medicine | 1996-01-01 |
| A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies (NCT00051597) | Seagen Inc. | |